-+ 0.00%
-+ 0.00%
-+ 0.00%

Passage Bio posts updated interim data from Phase 1/2 upliFT-D trial of PBFT02

PUBT·04/20/2026 11:03:02
Listen to the news
Passage Bio posts updated interim data from Phase 1/2 upliFT-D trial of PBFT02
  • Passage Bio reported updated interim Phase 1/2 upliFT-D data for gene therapy candidate PBFT02 in frontotemporal dementia with GRN mutations, with results already presented in this update.
  • Treated patients earlier in disease course showed signs consistent with slower neurodegeneration versus natural history, while more advanced patients did not show a similar benefit.
  • FDA feedback from a Type C meeting indicated a randomized controlled registrational trial will be required, undermining plans for a single-arm pathway and raising execution, cost, and feasibility hurdles.
  • Passage Bio initiated a strategic review to maximize shareholder value as it reassesses next steps for PBFT02 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200700PRIMZONEFULLFEED9692439) on April 20, 2026, and is solely responsible for the information contained therein.